Cargando…
SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases
Dopamine agonist monotherapy is first line therapy in giant prolactinomas even when visual field defect is present. The costlier cabergoline is often preferred over bromocriptine due to higher efficacy and tolerability profile. Described herein combined cabergoline and bromocriptine therapy in 6 cas...
Autor principal: | Kuan, Yueh Chien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208064/ http://dx.doi.org/10.1210/jendso/bvaa046.1664 |
Ejemplares similares
-
SAT-474 Giant Prolactinoma Case Series Assessing Response on Initial Dose of Cabergoline
por: Madan Paramasivan, Ameena, et al.
Publicado: (2019) -
SUN-448 Giant Prolactinomas: A Follow-Up of 25 Years with Dopamine Agonists
por: Mallea Gil, Susana, et al.
Publicado: (2019) -
SAT-455 Analysis of a Group of Prolactinomas Resistant to Treatment with Dopamine Agonists at a University Hospital in Buenos Aires, Argentina
por: Gonzalez Pernas, Mariana, et al.
Publicado: (2019) -
SAT620 Dopamine Challenge: Treatment Of Pituitary Macroadenoma/Prolactinoma In Patient On Antipsychotic Medication
por: Bazhenov, Aleksei, et al.
Publicado: (2023) -
SAT604 An Extensively Invasive Giant Prolactinoma Associated With CDH23 Mutation
por: Alghamdi, Balgees, et al.
Publicado: (2023)